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ABSTRACT 
The melanocortin 4 receptor (MC4R) is a G-protein coupled receptor mainly expressed in the 
central nervous system of vertebrates. Activation of the MC4R leads to a decrease in food 
intake, while inactivating mutations are a genetic cause of obesity. The binding of agouti-
related protein (AGRP) reduces agonist-stimulated cAMP production (competitive 
antagonist) but also the basal activity of the receptor, as an inverse agonist. Transgenic 
zebrafish overexpresing AGRP display increased food intake and linear growth, indicative of 
a physiological role for the melanocortin system in the control of the energy balance in fish. 
We report on the cloning, pharmacological characterization, tissue distribution and detailed 
brain mapping of a sea bass (Dicentrarchus labrax) MC4R orthologue. Sea bass MC4R is 
profusely expressed within food-intake controlling pathways of the fish brain. However, the 
activity of the melanocortin system during progressive fasting does not depend on the 
hypothalamic/pituitary proopiomelanocortin (POMC) and MC4R expression, which suggests 
that sea bass MC4R is constitutively activated and regulated by AGRP binding. We 
demonstrate that AGRP acts as competitive antagonist and reduces MTII-induced cAMP 
production. AGRP also decreases the basal activity of the receptor as an inverse agonist. This 
observation suggests that MC4R is constitutively active and supports the evolutionary 
conservation of the AGRP/MC4R interactions. The inverse agonism, but not the competitive 
antagonism, depends on the presence of a phosphodiesterase inhibitor (IBMX). This suggests 
that inverse agonism and competitive antagonism operate through different intracellular 
signalling pathways, a view that open up new targets for the treatment of melanocortin-
induced metabolic syndrome.  
  
Keywords: Melanocyte-stimulating hormone (MSH), Proopiomelanocortin (POMC), MC4R, 
Constitutive Activity, IBMX, Obesity.  
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INTRODUCTION 
 
Melanocortins are posttranscriptional products of a complex precursor named 
proopiomelanocortin (POMC). They are mainly comprised of adrenocorticotropic hormone 
(ACTH) and melanocyte-stimulating hormones (α-, β- γ- and δ-MSH; 26). POMC is 
produced in the pituitary but two discrete groups of neurons in the hypothalamus and the 
medulla of the central nervous system (CNS) of rodent also produce this precursor (22). 
Melanocortin signalling is mediated by binding to a family of specific G protein-coupled 
receptors that stimulate adenylyl cyclase activity. In vertebrates, five melanocortin receptors 
(MC1R-MC5R) have been characterized by molecular cloning. Subtype 2 receptor is ACTH 
specific, whereas the other four MCRs distinctively recognize MSHs (55). Expression studies 
in mammalian species have demonstrated that only MC3R and MC4R are significantly 
expressed within the CNS (22). The melanocortin system is not exclusively regulated by the 
binding of endogenous agonists, since naturally occurring antagonists, agouti (AG) and 
agouti related protein (AGRP), compete with melanocortin peptides for MCRs. Agouti 
protein is a potent antagonist at MC1R and MC4R (44), whereas AGRP is inactive at MC1R 
but equally potent in inhibiting melanocortin signalling at MC3R and MC4R (56).  
A body of evidences substantiates an essential role for central signalling through MC3R and 
MC4R in the regulation of energy intake and expenditure in mammalian species (22). Mice 
lacking MC4R exhibit hyperphagia, hyperinsulinemia, increased linear growth and obesity 
(35). A similar phenotype is also observed in mice over-expressing agouti or AGRP genes 
(38, 42, 52). Central administration of the MCR agonist, MTII, produces a dose-dependent 
reduction in food intake in mice (28) but not in MC4R-deficient mice (43). These anorexic 
effects are blocked by the co-administration of AGRP (53), which is endogenously released 
from the NPY neurons in the arcuate nucleus (32). Recent experiments have demonstrated 
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that AGRP is processed intracellulary by proprotein convertases into the active form AGRP 
83-123 (24). AGRP and MSH terminals co-localize in the MC4R-expressing neurons (4). 
However, the presence of AGRP terminals in MC4R-expressing neurons lacking MSH 
innervation (29) suggests that AGRP has effects on MC4R not only as competitive 
antagonist. In vivo experiments with mutant mice that exhibit a neural selective POMC 
deficiency have demonstrated that AGRP modulates the energy balance via a mechanism 
independent of MSH and MC3/4R competitive antagonism (61). MC4R has been reported to 
display constitutive activity, as it increases basal cAMP production in the absence of ligand 
(50) by spontaneously mimicking an agonist-occupied state (59). Several in vitro experiments 
have demonstrated that AGRP binding to MC4R decreases basal cAMP production (18, 20, 
33, 36, 50, 59), to suppress constitutive activity of the receptor. This suggests that AGRP not 
only blocks the agonist activity, but also stabilizes the inactive conformation of the receptor, 
and thus either suppresses or reduces the constitutive activity as an inverse agonist does. This 
constitutive activity may support a tonic satiety signal required for the long-term energy 
homeostasis that is ultimately regulated by AGRP (22, 59).   
We previously demonstrated that the melanocortin system may play a physiological role in 
the control of food intake in teleost fish. The central administration of melanocortin agonist 
inhibits food intake, whereas MC4R antagonist increases intake levels in fed animals (14, 
15). Short- or long-term fasting does not induce changes in hypothalamic POMC expression 
(15) but sharply increases hypothalamic AGRP production (13). Experiments in zebrafish 
have further demonstrated that AGRP acts as a competitive antagonist at MC4R, while gene 
overexpression in transgenic models results in obesity and increased linear growth (57). 
Immunocytochemical studies revealed differential densities of AGRP and α-MSH terminals 
in discrete brain areas, in line with an α-MSH-independent AGRP activity (30). The 
evolutionary conservation of the AGRP inverse agonism and the MC4R constitutive activity 
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remains unexplored. We first approached this question by molecular cloning and 
pharmacological characterization of sea bass MC4R. We also studied the distribution of the 
MC4R-mRNA in the brain and the response of the central and peripheral (pituitary) 
melanocortin system to progressive fasting. Our results provide the first evidence 
demonstrating that AGRP acts as an inverse agonist at MC4R in non-mammalian species and 
suggest that the sea bass receptor is constitutively active. Furthermore, we show that the 
inverse agonism of AGRP, but not the competitive antagonism, depends on 
phosphodiesterase inhibition. Lastly, we provide physiological evidence supporting the 
constitutive activity of the sea bass MC4R.   
  
EXPERIMENTAL METHODS  
 
Animals and reagents  
Male and females sea bass (Dicentrarchus labrax) were kindly supplied by Tinamenor 
(Santander, Spain). Prior to the experiments, the animals were maintained in 500-litre tanks 
supplied with continuously aerated running sea water for two months. Fish were hand fed at 
9.00 am with a commercial diet (Proaqua Nutrición). Animals were anesthetized in 2-
phenoxy-ethanol (0.1%) for 2 min before any manipulation and sacrificed by rapid 
decapitation. All experiments were carried out in accordance with the principles published in 
the European animal directive (86/609/CEE) concerning the protection of experimental 
animals. Melanocortin peptides were from Bachem (Germany). Unless otherwise indicated, 
all reagents were purchased from Sigma (St Louis MO, USA).     
 
Molecular Cloning of Sea Bass MC4R 
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Genomic DNA isolated from blood was used as template for touchdown PCR reactions with 
Taq DNA polymerase (Invitrogen) and degenerate primers designed against conserved 
regions of the known MC4R sequences. The following reaction conditions applied: 0.2 mM 
dNTP, 0.4 μM FwFish and RevFish primers, 1 X Taq DNA polymerase buffer, 1.5 mM 
MgCl2 and 0.5 units Taq DNA polymerase. The 5´ primer (FwFish) was a 20-mer with the 
sequence: 5´ TAYATCACCATMTTYTACGC 3´. The 3’ primer (RevFish) had the sequence 
5´ TSAGVGTGATGGCKCCCTT 3´ (Fig.1). PCR products of about 300 base pair (bp) were 
isolated from low melting point (LMP) Nusieve GTG agarose gel (FMC) ligated into pGEM-
T easy vector (Promega) and subsequently transformed into XLI-Blue E. coli. One clone that 
contained an insert of expected size was sequenced.  
To resolve the 3’ end sequence of the sea bass MC4R cDNA, 3’ RACE-PCR was performed. 
For 3’ RACE PCR cDNA was synthesized using dT-adapter primer (5’ 
CAGTCGAGTCGACATCGA (T)17 3’). Two rounds of PCR amplified the 3’ end with 
adapter (5’ CAGTCGAGTCGACATCGA 3’) and sbMC4R_3´RACE_1 (5’ 
GTTGGTCATCAGCAGCAT 3’) primers and then adapter primer and sbMC4R_3´RACE_1 
(5’ GCATCCTGTTTATCATCTAC 3’, Fig. 1). After LMP purification a 532-bp fragment 
was subcloned into pGEM-T easy vector and sequenced. The 5´region was cloned using the 
Genome Walker Kit (Clontech) and following manufacturer’s instruction. Specific primers 
for genome walking were sbMC4R_5Walker_1 primer (5’ 
GCAATGCTGCGATGCGCTTCATGTGCA 3’) for the first PCR and sbMC4R_5Walker_2 
primer (5’ GTCCAGATGCTGCTGATGACCAACATTGC 3´) for the nested PCR (Fig.1). A 
547-bp fragment was subcloned into pGEM-T easy vector and sequenced. Finally, the full 
coding region was amplified by PCR, using genomic DNA as template and the primers Hind-
MC4R-Forward (5' TATAAGCTTATGAACACCACAGAGGCTC 3') and XhoI-MC4R-
Reverse (5’ TATCTCGAGGAGTCGTAGCTGCTGCTC 3’, Fig.1). A 1036-bp DNA 
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fragment was subcloned into pGEM-T easy vector and sequenced on both strands. The 
nucleotide sequence of sea bass MC4R has been deposited with EMBL Nucleotide Sequence 
Database under accession numbers FM253127. 
 
RT-PCR and Southern blot analysis 
Total RNA was purified from fresh tissues (testis, ovary, intestine, fat, liver, white and red 
muscle, spleen, head kidney and kidney body proper, gill, dorsal skin, ventral skin, retina, 
heart, pituitary and brain) and treated with RQ1-DNAse (Promega). Superscritp II reverse 
transcriptase (Invitrogen) was used for cDNA synthesis by priming with oligo (dT)12-18 
(Invitrogen). The cDNA was subsequently used as template for touchdown PCR reactions 
with Taq DNA polymerase (Invitrogen) and specific primers. The 5’ primer was 
sbMC4R_3´RACE_1 (see above) and the 3’ primer (sbMC4R_cDNA_synthesis) had the 
sequence 5’ CAAGTGATCATGAGGATGA 3’ (Fig.1). Subsequently, PCR fragments were 
separated onto 1.2 % agarose gel, transferred by capillarity to Hybond-N nylon membrane 
(Amersham). Membranes were prehybridized for at least 3 hours in hybridization solution 
(50 % formamide, 6X SSPE, 0.5 % SDS, 5 X Denhardt’s solution and 10 mg/ml yeast tRNA 
type III, 1 X SSPE containing 150 mM NaCl, 1 mM EDTA, 9 mM NaH2PO4, pH = 7.4). 
Hybridization was carried out overnight in fresh hybridization solution containing 0.5 X 106 
cpm/ ml dCTP [α-32P] at 42 °C. A 301-bp probe containing the central region of the sea bass 
MC4R coding region was used. Final washes were performed in 0.1 X SSPE at 65 °C. After 2 
hours and 3 days of exposure at -80 ºC films were developed and scanned. As internal control 
of the reverse transcription step, touchdown PCR for 18S RNA was carried out. Primer 
sequences were 18S_Forw 5’ GCATGCCGGAGTCTCGTT 3’ and 5’ 18S_Rev 5´ TGCATG 
GCCGTTCTTAGTTG 3´. 
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Real time quantitative PCRs 
To evaluate gene mRNA levels, total RNA from individual hypothalamus or pituitary was 
treated with RQ1-DNAse. One microgram was used as template for cDNA synthesis, which 
was primed with random hexaprimers (Invitrogen). Two microliters of cDNA (POMC and 
MC4R) or diluted cDNA (18S RNA) and primers (70 nM) were added to 7.5 μl of Sybr green 
PCR master mix (ABgene, Thermo Scientific, Spain) and the volume was adjusted to 15 μl 
with water. PCRs were carried out on an iCycler (Bio-Rad, Madrid, Spain). Data were 
analyzed with the ΔΔCt (cycle threshold) method. As internal control a fragment of the sea 
bass 18S RNA gene was amplified, using primers 18S_Forw and 18S_Rev primers (see 
above). Specific gene primers were as follow: sbMC4R_For_a: 
5´ATGAACACCACAGAGGCTCA3´, sbMC4R_Rev_a 5' ATAGCATCC 
TGTGGACGAGT 3´ for sea bass MC4R (Fig.1) and sbPOMC_Forw_1 5´ 
ATGTGTCCTGTGTGGTTATTG 3', sbPOMC_Rev1 5´ GCGACAGAGCTGGATACA 3' 
for sea bass POMC (62).  
 
In situ hybridization 
In situ hybridization experiments were carried out as described previously. Animals were 
anaesthetized, then transcardially perfused with 50 ml of physiological saline solution (NaCl 
0.65%) and subsequently perfused with the same volume of fixative containing 
paraformaldehyde (PAF, 4%) in phospate buffer (PB, 0.1 M pH 7.4). After decapitation, the 
brains were removed, post-fixed overnight in the same fixative at 4ºC, dehydrated, and 
embedded in Paraplast (Sherwood, St Louis, MO). Serial 6 μm cross sections were cut using 
a rotary microtome. One section every 200 μm was mounted on 3-aminopropyltriethoxylane 
(TESPA)-treated slides and then air-dried at room temperature (RT) overnight. Three 
consecutive series covering the length of the sea bass brain were made. Two series were used 
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for hybridization with the sense and anti-sense probes. The last series was stained with 
cresyl-violet 0.1% for detailed identification of brain nuclei. Sections were stored at 4ºC 
under dry conditions and used for hybridization within one week.  
Before hybridization, sections were deparaffinized, rehydrated and post-fixed in 4% PAF for 
20 minutes. Slides were then rinsed twice in PB for 5 minutes and treated with a Proteinase-K 
solution (20 μg/ml in 50 mM Tris-HCl, 5mM EDTA, pH = 8) for 5 minutes at RT. Slides 
were then washed in PB and post-fixed again in PAF for 5 minutes, subsequently rinsed in 
sterile water and acetylated in a triethanolamine (0.1 M, pH 8) / acetic anhydride solution. 
Sections were then dehydrated and dried at RT.  
The entire coding region of the seabass MC4R receptor sequence was cloned into pGEM-T 
easy vector (Promega). Anti-sense and sense RNA probes were synthesized in vitro by 
linearizing the plasmid with NcoI and Sal I (Takara). In vitro transcription was carried out 
with SP6 or T7 RNA polymerase, respectively. Both sense and anti-sense probes were 
labelled with 10 μl of 35S-UTP (10 mCi / ml) using a riboprobe synthesis kit (Promega, 
Barcelona, Spain) as described by the manufacturer. After in vitro RNA synthesis, samples 
were treated with RQ1-DNAse for 15 minutes at 37ºC in presence of 50 units of RNAsin 
(Promega) and then incubated at -20ºC for 3 hours with 10 μg/ml of yeast RNA type III in an 
8% formamide solution. Probes were subsequently purified using Sephadex G50 columns. 
The two fractions containing the highest radioactivity level were pooled and precipitated in 
ethanol-sodium chloride at -20ºC. The labelled probes were then stored at -20ºC and used 
within one week.  
The 35S-UTP riboprobes were pelleted and dissolved in an appropriate volume of 100 mM 
DTT to obtain 2x105 cpm/μl. After 5 minutes incubation at 80ºC, 35S-UTP riboprobes were 
diluted 1/10 (final concentration of probes, 10 mM DTT and 2x104 cpm/μl) in hybridization 
buffer containing 50% formamide, 300 mM NaCl, 20 mM Tris-HCl (pH 8), 5 mM EDTA 
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(pH 8), 10% Dextran sulphate, 1x Denhardt´s solution and 0.5 μg/ml yeast RNA type III. 
Subsequently, 100 μl of hybridization solution was added to each pre-treated slide (see 
above), which were cover-slipped and incubated in a humidified chamber at 55ºC overnight. 
The following day coverslips were removed by incubating slides in a solution containing 5x 
standard saline citrate buffer (SSC, 1x SSC containing 150 mM NaCl, 15 mM sodium citrate, 
pH 7), 10 mM DTT, for 30 minutes at 55ºC. The slides were then rinsed in 2xSSC, 50% 
formamide, 10 mM DTT for 30 minutes at 65ºC and three times immersed in NTE buffer 
(500 mM NaCl, 10 mM Tris-HCl, 5 mM EDTA, pH 7.5) for 10 minutes at 37ºC. After 
RNAse treatment (20 μg / ml RNAse in NTE) for 30 minutes at 37ºC, slides were rinsed 
three times in NTE buffer for 10 minutes at 37ºC, once in 2x SSC, 50% formamide, 10 mM 
DTT for 30 minutes at 65ºC, once in 2xSSC for 15 minutes at RT and twice in 0.1x SSC for 
15 minutes at RT. Slides were finally dehydrated in increasing degrees of ethanol solutions 
containing 0.3 M ammonium acetate and dried at RT. After the hybridization process, slides 
were dipped in photographic emulsion (Amersham) and exposed under dry conditions at 4ºC 
for 5 to 7 days, developed in Kodak D-19 and counter-stained with toluidine blue 0.02%. 
Anatomical locations were confirmed by reference to a brain atlas of sea bass (12, 16, 17). 
 
Peptide synthesis, purification and folding 
Zebrafish AGRP (Ac-83-127-NH2) was synthesized using Fmoc synthesis on an Applied 
Biosystems (Foster City, CA) 433A Peptide Synthesizer on a 0.25mmol scale. The synthesis 
was monitored using the SynthAssist version 2.0 software package. The peptide was 
assembled on a Rink-amide-MBHA resin and pre-activated Fmoc-Cys(trt)-OPfp was used. 
All amino acids and resins were purchased through NovaBiochem (San Diego, CA). HBTU 
was obtained from Advanced Chemtech (Louisville, KY). Fmoc deprotection was achieved 
using a 1% hexamethyleneimine and 1% 1,8-Diazabicyclo[4.5.0]-undec-7-ene solution in 
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DMF. Deprotection was monitored by conductivity and continued until the conductivity level 
returned to the baseline, then synthesis resumed. Deprotection time ranged from 2.5-7 
minutes. Coupling used 4 equivalents Fmoc-amino acid in HBTU/DIEA for all amino acids 
with the exception of pre-activated Cysteine. A 3-fold excess of Fmoc-Cys(Trt)-OPfp was 
dissolved in 1.5mL 0.5M HOAt/DMF with no DIEA for coupling. The peptides were N-
terminal acetylated by reacting with 0.5M acetic anhydride in DMF for 5 minutes. Fully 
synthesized peptide resin was split into 3 reaction vessels, washed with DCM and dried. A 
solution of 8mL TFA containing 200μL each of TIS/EDT/liquefied Phenol (as scavengers) 
was added to each reaction vessel of dry peptide resin for 1.5h. The resin was filtered and 
washed with 1mL TFA and the combined filtrate and wash was then added to 90mL cold dry 
diethyl ether for precipitation. The precipitate was collected by centrifugation and the ether 
was discarded. The pellet was dissolved in 40mL 1:1 H2O:Acetonitrile (0.1% TFA) and then 
lyophilized.  
The crude peptide was purified by RP-HPLC on C4 Vydac (Hesperia, CA) preparative 
columns. Fractions were collected and analyzed by ESI-MS on a Micromass (Wythenshawe, 
UK) ZMD mass spectrometer to confirm the correct molecular weight. Fractions containing 
the peptide as a major constituent were combined and lyophilized.   
Air oxidative folding of zAgRP was accomplished by dissolving the unfolded peptide into 
folding buffer (2.0M GuHCl/0.1M Tris, 3mM GSH, 4 mM GSSG, pH 8) at a peptide 
concentration of .1mg/mL) and stirring for 14h. Folding was monitored by reversed phase 
(RP)-HPLC on a C18 analytical column, which revealed a single peak for the folded material 
that shifted to an earlier retention time than the fully reduced peptide and ESI-MS indicated a 
difference of 10 amu. The folded product was purified by RP-HPLC on a C18 preparative 
column and its identity confirmed as the fully oxidized product by ESI-MS (AGRP Ac-83-
127-NH2: 5287.1 calc. ave. isotopes 5288 amu obs.). Reinjecting a small sample of the 
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purified peptide on an analytical RP-HPLC column assessed purity of the peptide. 
Quantitative analysis of the peptide concentration was carried out by amino acid analysis at 
the molecular structure facility at UC Davis.  
 
Cell culture and transfection  
If not specifically indicated, HEK cells were transfected using a modified calcium phosphate 
transfection method (20) and grown in DMEM (Invitrogen) containing 10% foetal bovine 
serum (Invitrogen), penicillin (100 units/ml) and streptomycin (100 μg/ml) in a humidified 
atmosphere of 5% CO2 at 37ºC. 
 
Galactosidase enzyme assay  
Galactosidase enzyme assays were performed as previously described (21). Briefly the 
medium was removed and 50 μl of lysis buffer containing 250 mM Tris-HCl pH=8 and 0.1 % 
Triton X-100 were added. After one round of freezing (-80 ºC) and thawing, ten microlitres 
of the lysate were preserved for protein assays. Forty microliters of phosphate saline buffer 
containing 0.5 % BSA and 60 μl of substrate buffer (1mM MgCl2, 10mM KCl, 5mM β-
mercaptoethanol and 200 mg/ml o-nitrophenyl-β-D-galactopyranoside, ONPG) were added 
to the remaining lysate volume. The plate was incubated at 37 ºC for 5h and the absorbance 
was read at 405 nm in a 96-well plate reader (Tecan). Measurements were normalized by the 
protein content determined using the BCA protein assay kit (Pierce). 
 
Pharmacological experiments  
A HEK-293 cell clone, stably expressing β-galactosidase under the control of vasoactive 
intestinal peptide promoter placed downstream of tandem repetitions of cAMP responsive 
elements (CRE, 21), was generated by co-transfection (50:1) of pCRE/β-galactosidase 
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plasmid (kindly supplied by Dr. R Cone, Vanderbilt University Medical Center) and the 
tgCMV/HyTK plasmid, which harbours a hygromycin resistance gene (65). Cells were 
selected in medium containing 400 μg/ml of hygromycin B (Invitrogen). β-galactosidase 
activity was tested after incubating resistant clones in 96-well plates (15.000 cells/well) 
with assay medium (DMEM medium + 0.1mg/ml bovine serum albumin, BSA + 0.1 mM 
isobutylmethylxanthine, IBMX) containing 10 -6 M forskolin during 6 hours. The clone 
showing highest response to forskolin (Clon-Q) was selected for subsequent experiments. 
The full coding region of the sea bass MC4R was released from pGEM-T easy vector (see 
above) and subcloned into pcDNA3 (Invitrogen). Double stable clones expressing β-
galactosidase and sea bass MC4R were made by transfecting Clon-Q with the latter 
construct using G-418 selection (800 μg/ml). Clones were tested by incubating cells with 
MTII 10-6 M in the assay medium. The clone Q/9 was selected for the characterization of 
the activation profiles in response to several melanocortins (α-MSH, diacetyl-MSH, 
desacetyl-MSH, human ACTH, monkey β-MSH, zfAGRP, SHU9119 and HS024) in the 
absence of IBMX. The effect of zfAGRP on basal and MTII-stimulated MC4R activity 
was studied in both the presence and absence of the phosphodiesterase inhibitor. MC4R 
activation assays were performed in quadruplicate wells and repeated at least three times 
independently.      
For saturation experiments, intact Q/9 cells were incubated in a final volume of 75 μl for 
2.5 h at 37 °C and carried out with serial dilutions of [125I][Nle4, D-Phe7]α-MSH (NDP-
MSH). Non-specific binding was defined as the amount of radioactivity remaining bound 
to the intact cells after incubation in the presence of 10 μM unlabelled NDP-MSH. 
 
Effects of progressive fasting on melanocortin system 
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To evaluate the effects of fasting on hypothalamic and pituitary gene expression, ten groups 
of 10 fish each [body weight (BW) = 117 ± 1.54 g] were adapted for one-week to individual 
500-liter aquaria and fed ad libitum at 9.00 a.m. After this acclimation period, five groups 
were fed a same ratio whereas five others were fasted. One each fed or fasted groups was 
sampled at 12.00 (3 hours post-feeding for fed groups) at 1, 4, 8 and 15 and 29 days, 
respectively. Anesthetized fish were weighed and blood samples were obtained by puncture 
of the caudal vessels. Subsequently the fish were decapitated and the whole hypothalamus 
and pituitary dissected for immediate total RNA extraction. RNA samples were kept at –80C 
in 75% ethanol until cDNA synthesis for quantitative PCRs (see above). Plasma was stored at 
-80 until assayed.  
 
Hormone measurements 
Plasma α-MSH was measured by radioimmunoassay according to (3). 
 
Data analysis and statistics 
Sequence comparisons and alignments were performed using ClustalX. A phylogenetic tree 
was derived using public domain CulstalX, which uses the Neighbor-Joining method on a 
matrix of distances. The membrane protein secondary structure was predicted using the Split 
4.0 Server (http://split.pmfst.hr/split/4/). Receptor activation data were fitted using SigmaPlot 
software. In gene expression studies, specific mRNA levels were normalized as a ratio to 18S 
RNA. Statistical analysis was conducted by one-way analysis of the variance followed by 
Tukey´s multiple range test (p<0.05).    
 
RESULTS 
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Molecular cloning of seabass MC4R  
By means of RT-PCR and using degenerate primers designed against conserved regions of 
fish melanocortin receptor sequences, we cloned a 301 bp fragment showing high identity to 
the MC4Rs reported in other vertebrate species. The 3´extreme was resolved by 3´RACE 
PCR, whereas the sequence of the 5´end was obtained by PCR screening of a partial genomic 
library. The full cDNA sequence was obtained by PCR amplification of genomic DNA. As 
with most MCRs, the coding region of the putative sea bass receptor does not contain introns. 
The cloned fragment contains an open reading frame of 981 bp that encodes a putative 327-
amino acid protein with seven putative hydrophobic transmembrane domains (TMDs, Fig. 1, 
2). Similar to other melanocortin receptors, the sea bass MC4R orthologue exhibits short 
extracellular (ECL) and intracellular (ICL) loops and shares cysteine residues at positions 
258, 272 and 278 (sea bass numbering) which are fully conserved in all melanocortin 
receptors (Fig. 2 and http://www.gpcr.org). The deduced amino acid sequence displays 
potential N-glycosylation sites within the N-terminal domain at positions 2 and 15 and one 
additional site within the first extracellular loop (ECL, position 97, Fig. 1). This predicted 
ECL is considerably longer than the second and third ECLs that are only four amino acids 
long. Similarly, the third intracellular loop (ICL) is more extensive than the first and second 
predicted ICLs, which are only six amino acids long. In addition, sea bass MC4R shares the 
PMY motif in the second TMD that is conserved in most melanocortin receptors. The 
deduced amino acid sequence is 67% and 86% identical to human and pufferfish MC4R, but 
only 48, 40, and 63% identical to pufferfish MC1R, MC2R and MC5, respectively and 60 % 
identical to zebrafish MC3R. The identity is unequally distributed and the N-terminal 
extracellular domain displays the lowest identity level to other MC4Rs, including pufferfish 
MC4R. More than 30% of the divergence between sea bass and human MC4R orthologues 
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resides within the N-terminal domain, encoding only 14 % of total protein length. A more 
detailed comparison shows that the overall identity level of sea bass receptor to other MC4Rs 
is highest (>94%) within the TMD2 and lowest in the TMD4 (<57%). The overall identity 
ranged between 80 and 86% within the TMD3, TMD6 and TMD7 and between 75 and 77% 
within the TMD1 and TMD5.   
 
Peripheral and central distribution of MC4R mRNA 
RT-PCR with specific primers targeting sequences within TMD4 and TMD6 of the sea bass 
MC4R (Fig. 1) resulted in a band of the expected size of about 321 bp. The identity of the 
band was confirmed by Southern blot hybridization with a sea bass MC4R probe including 
the full coding region. Sea bass MC4R mRNA was easily detected in the retina, brain and 
pituitary gland but very low levels were also distinguished in the liver, fat tissue, testis and 
white muscle (Fig. 3A). No bands or hybridization signal for goldfish MC4R were obtained 
in PCR reactions using spleen, gill, intestine, dorsal and ventral skin, red muscle, heart and 
ovary cDNAs or water (control) as template (Fig. 3A). Inverse transcriptions and cDNA 
quality were corroborated by PCR amplification of 18S RNA that yielded bands of expected 
size in all reactions (Fig. 3B).  
To further characterize neuronal expression of MC4R mRNA, we used the in situ 
hybridization technique. Hybridization with sense MC4R-cRNA probes never generated 
specific signals in the sea bass brain (data not shown), in support of the probe specificity. 
Figure 4 schematically represents the distribution of MC4R mRNA within sea bass brain. 
Cell groups expressing MC4R mRNA were detected in the following areas: telencephalon, 
preoptic area, hypothalamus, ventral thalamus, tectum mesencephalic and rombencephalon. 
The first MC4R-expressing neurons were localized in the caudal and rostral regions of the 
dorsal (Vd) and ventral (Vv) part of the ventral telencephalon, respectively (Fig. 4A). At the 
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same level, some large cells expressing MC4R could be detected in the central region of the 
dorsolateral part of the ventral telencephalon (Dlv, Fig. 4A). Just prior to the opening of the 
preoptic recess, a conspicuous population of large MC4R-expressing cell bodies was found in 
the central part of the ventral telencephalon (Vc, Fig. 4B). At this level, some scattered 
MC4R-expressing perikarya were observed in the posterior part of the ventral telencephalon 
(Vp Fig. 4B). Within the dorsal telencephalon, some MC4R-expressing cell bodies were 
placed in the caudal area of the medial part (Dm, Fig. 4A).    
Positive MC4R-labeled neurons were evident in several parts of the preoptic area. The most 
rostral positive cells were those of the rostral pole of the parvocellular preoptic nucleus 
(NPOpc), also named as anterior periventricular nucleus in other species, located at the level 
of the preoptic recess entrance. MC4R-mRNA expressing neurons of the NPOpc are found at 
periventricular positions where almost all neurons seem to be melanocortin dependent (Fig. 
4B and 5A,B). Slightly more caudally, profuse MC4R mRNA expression was found in the 
magnocellular neurons of the preoptic nucleus (PM, Fig. 4C and 5C,D). Progressively caudal, 
MC4R positive perikarya were found in the periventricular anterior (NAPV) and in the 
ventral pole of the preoptic area that coincides with the suprachiasmatic nucleus (NSC, Fig. 
4C and 5C,D).    
Within the tuberal hypothalamus, almost all divisions were found to profusely produce 
MC4R mRNA. MC4R mRNA-expressing cell bodies were found in the dorsal (NLTd) and 
ventral (NLTv) parts of the lateral tuberal nucleus (Fig. 4D and 5E,F). In the NLT, MC4R 
neurons lined the third ventricle and most periventricular neurons appeared to make contact 
with the ventricular wall (data not shown). More caudally, a profuse population of MC4R-
mRNA expressing cell bodies were located in the dorsal (NRLd) and ventral (NRLv) parts of 
the lateral recess nucleus (Fig. 4E and 5E, F, G, H). At this level, a distinct population of 
MC4R-mRNA expressing cells is placed in the medial part of the diffuse nucleus of the 
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inferior lobe (NDLIm, Fig. 4E, F and 5G,H). Some MC4R producing cells were also 
observed in the medial area of the lateral tours (TLa, Fig. 4F). MC4R-mRNA expressing cells 
also coat the entire rostro-caudal extension of the lateral recess forming the lateral part of the 
lateral recess nucleus (NRLl, Fig. 4F, G and 5G, H).  
In the thalamus, MC4R mRNA-expressing neurons were restricted to the ventromedial 
nucleus of the ventral thalamus (Fig. 4D, 5I-J). A profuse expression was further found in the 
outer layer of the periventricular gray zone (PGZ) of the mesencephalic tectum (Fig. 4D-G). 
Finally, in the rombencephalon, MC4R producing cells were placed in the superior reticular 
nucleus of the reticular formation (RS, Fig 4G, 5K-L). No MCR4-mRNA expression was 
detected in the pituitary by in situ hybridization.         
 
Fasting effects on melanocortin system of the sea bass  
Quantitative PCR did not yield significant differences in hypothalamic POMC- and MC4R-
mRNA expression levels when fed and fasted animals were compared after 1, 4, 8 15 and 29 
days of fasting (Fig. 6A). Similarly, no differences in pituitary POMC expression (Fig. 6A) or 
plasma MSH levels (Figure 6B) were detected after progressive fasting.       
 
Binding and activation by melanocortin analogs 
For pharmacological and functional characterization of the sea bass MC4R, the coding region 
was ligated into pcDNA3 and stably expressed in HEK 293 cells already producing β-
galactosidase under the control of cAMP responsive elements. Saturation experiments 
displayed a single saturable site for [125I]-NDP-MSH (Fig. 7A) and that the receptor binds 
this agonist in a similar manner to that of the human, zebrafish abnd goldfish MC4R (14). 
The sea bass MC4R is not activated by potential melanocortin antagonists such as SHU9119, 
HS024 or zfAGRP. However, sea bass MC4R is positively coupled to the cAMP-signaling 
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pathway in response to diacetyl-MSH with a half-maximal effective concentration (EC50) of 
0.094 nM. Sea bass MC4R activation by α-MSH and monkey β-MSH showed an EC50 of 
0.822 nM and 3.333 nM, respectively, whereas effective concentration increased to 18.8 nM 
and 15.13 nM when cells were incubated with human ACTH or desacetyl-MSH (Fig 7). Sea 
bass MC4R was also activated by the non-selective melanocortin agonist MTII (EC50= 0.31 
nM). However, MTII-stimulated cAMP intracellular accumulation decreased by co-
incubation with 1 μ M of HS024 (EC50=17 nM) , SHU9119 (EC50=120 nM) and zfAGRP 
(EC50=85 nM; Fig. 8). When a phosphodiesterase inhibitor (IBMX) was added to the 
medium, the response of the reporter gene to the MTII incubation increased (EC50=0.01 nM, 
Fig. 9). However, the incubation of sbMC4R-expressing HEK cells with AGRP in the 
presence of IBMX sharply decreased the basal activity of the receptor as an inverse agonist 
would (IC50= 1.14 nM). Under these conditions, AGRP also decreased MTII-stimulated 
cAMP production (EC50=9.9 nM) as a competitive antagonist would.    
 
DISCUSSION 
 
The present study demonstrates that AGRP acts as an inverse agonist at sea bass MC4R. 
However, the inverse agonism, but not the competitive antagonism, is dependent on the 
presence of a phosphodiesterase inhibitor in the culture medium. Our results demonstrate that 
sea bass MC4R is profusely expressed within food-intake controlling pathways of the fish 
brain. However, the activity of the melanocortin system during progressive fasting does not 
depend on the hypothalamic/pituitary POMC and MC4R expression, which suggests that sea 
bass MC4R is constitutively activated and regulated by AGRP binding.   
Sequence comparisons show that the cloned receptor in the sea bass displays higher identity 
to pufferfish MC4R than to other fish MCR. Both pufferfish and zebrafish MC4Rs have 
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previously been shown to display strong phylogenetic relationships with their respective 
mammalian counterparts (40, 56). Our phylogenetic analysis supports that this new gene is an 
MC4R orthologue (data not shown). In rodents, MC4R expression is restricted to the central 
nervous system (47). Studies in chicken (60) and goldfish (14) have demonstrated that MC4R 
is also expressed in the peripheral tissues, and this suggesting a participation of the receptor 
in the peripheral function of the melanocortin peptides (14). In the sea bass, MC4R 
expression was limited to the neural tissue, as occurs in mammalian models, with some 
residual expression in the adipose tissue, white muscle and testis. A high expression level of 
sea bass MC4R was also detected in the pituitary gland by RT-PCR, although in situ 
hybridization studies were unable to demonstrate MC4R-mRNA producing cells in the gland. 
This discrepancy may be accounted by hypothalamic contamination of the hypophyseal tissue 
during the pituitary dissection or by differences in technique sensitivity.  
To further understand the regulation of the central melanocortin signaling and its involvement 
in the circuits controlling food intake, we studied MC4R-mRNA distribution in sea bass brain 
by in situ hybridization. Receptor transcripts were restricted to the telencephalon, preoptic 
area, ventral thalamus, hypothalamus, optic tectum and rombencephalon. So far, no studies 
on central α-MSH/AGRP distribution in the sea bass were published but MC4R-mRNA 
distribution is in perfect agreement with previous studies on the AGRP (30) and α-MSH-like 
immunoreactive (ir) fiber distribution in the teleost brain (2, 30, 51). In this group of fish, 
POMC and AGRP are expressed in different populations of the lateral tuberal nucleus (13, 
15, 30). In zebrafish, both AGRP and POMC neurons project dorsally to innervate several 
thalamic areas, including the ventromedial nucleus where we have demonstrated MC4R 
expression (30). The main α-MSH/ AGRP fiber aggregation passes through the caudal region 
of the preoptic area (anterior periventricular nucleus, NAPv and suprachiasmatic nucleus, 
NSC) to densely accumulate at the lateral aspect of the magnocellular preoptic nucleus (PM). 
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All nuclei are melanocortin responsive areas expressing MC4R in sea bass brain. The PM is 
the only nucleus of the zebrafish brain where denser AGRP innervation was detected when 
compared to α-MSH-ir fibers. Interestingly, MC4R receptors in the goldfish PM are found in 
the lateral aspect of the nucleus and this perfectly matches the lateral aggregation (14) of α-
MSH/AGRP fibers reported for zebrafish (30). Our results suggest that most of the 
magnocellular cells i.e. lateral and periventricular cells, will be responsive to melanocortin 
peptides, via MC4R in the sea bass. Some of these cells in the preoptic nucleus of teleost fish 
also produce corticotrophin-releasing hormone (CRF, 1), which is thought to be a mediator of 
the appetite-suppressing effects of stress in fish (6). A recent report has demonstrated that the 
central anorectic effects of α-MSH in goldfish are mediated, in part, via CRF and describes 
the presence of melanocortin terminals in CRF-producing neurons (44). Both AGRP and α-
MSH neuronal systems also display an abundance of fibers within the rostral preoptic area 
that extend around the anterior commissure into the postcommissural (Vp) and 
supracommissural (Vs) nucleus of the zebrafish forebrain. Our present results demonstrate 
that MC4R is highly expressed within the rostral preoptic area including the parvocellular 
(NPOpc) and anteroventral (NPOav) pars of the parvocellular preoptic nucleus. A heavy 
innervation of α-MSH and, to a lesser extent, for AGRP was also detected in the dorsal (Vd), 
ventral (Vv) of the ventral telencephalon in zebrafish. All these areas have been demonstrated 
to be MC4R-producing areas of the sea bass brain. Additionally, we have demonstrated the 
presence of a conspicuous MC4R-expressing population within the caudal area of the central 
part of the ventral telencephalon (Vc). Previous studies in sea bass have demonstrated that 
cells in the Vv and Vc distinctly produce NPY (10, 11) suggesting the telencephalic 
interaction between both peptidergic systems. Only α-MSH-ir, but no AGRP-ir, fibers are 
found in abundance in the medial zone of the dorsal area of the zebrafish telencephalon (Dm), 
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where we have described MC4R expression in the sea bass. Ascending α-MSH- and AGRP-
projections have also been described in the periventricular gray zone and reticular formation 
of zebrafish (30), where we here report MC4R expression in the sea bass brain.  
Descending α-MSH/AGRP pathways in zebrafish display a high and moderate 
immunoreactivity density of α-MSH and AGRP, respectively, just caudally to the ventral 
hypothalamus and projecting dorsally through the caudal hypothalamus into the semicircular 
torus. Some positive terminals are also evident in the dorsal hypothalamus and inferior lobe. 
Similar results were reported for goldfish, in which the density of the ACTH-like fiber 
network is maximal in the ventral hypothalamus, particularly in the median part of the lateral 
tuberal nucleus towards areas around the lateral and posterior hypothalamic recess (51). In 
the sea bass, MC4R is profusely expressed within the whole extension of the lateral tuberal 
nucleus as well as in the inferior lobe including the nucleus of the lateral recess and 
semicircular torus. In summary, the localization of the sea bass MC4R is in good agreement 
with the reported distribution of α-MSH and AGRP terminals in other teleosts. 
Morphological comparisons between fish and mammalian brain are complex. Detailed 
distribution of MC4R expression has only been described in the murine species (4, 37, 41, 
47) and goldfish (14). The distribution of MCR in sea bass brain is similar to the pattern 
reported in goldfish but the number of discrete structures expressing MC4R seems to be 
lower than that reported in rat. This is especially patent within the posterior and midbrain, 
suggesting the acquisition of new central functions for MC4R in the mammalian lineage.  
Within the forebrain, the MC4R expression distribution seems to be well conserved. In rat, 
MC4R is profusely expressed in the hypothalamus including anteroventral periventricular, 
ventromedial preoptic, median preoptic, paraventricular, dorsomedial and arcuate nuclei. The 
preoptic and hypothalamic regions are highly variable among vertebrates, but the lateral 
tuberal nucleus is thought to be the teleostean homologue of the mammalian arcuate nucleus. 
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In addition, the parvo- and magnocellular neurons of the preoptic nucleus seem to be 
homologues of the mammalian supraoptic and paraventricular nuclei, all of them pivotal 
points in the control of the energy balance in mammalian species (7). Neuronal pathways 
involved in the control of food intake in fish are not well known. However, the tuberal 
hypothalamus, lateral torus and the inferior hypothalamic lobe have been suggested to be 
involved in the integration of the viscero-sensory information and elaboration of coordinated 
responses modifying the energy balance in fish (64). Therefore, our results support a role for 
MC4R in the main areas controlling food intake in fish.  
In mammals, the melanocortin system is a key regulator of body weight. Inactivation of the 
central MC4R leads to profound obesity, as does the hypothalamic over-expression of the 
endogenous antagonists, agouti and AGRP (22). Our previous studies have also demonstrated 
the participation of the melanocortin system in the regulation of food intake in fish, via 
central MC4R. Therefore, MTII inhibits feeding in fasted animals, whereas the selective 
MC4R antagonist, HS024, stimulates food intake in fed animals. Progressive fasting has no 
effects on hypothalamic POMC expression but dramatically stimulated AGRP production in 
the lateral tuberal nucleus (13-15). This strongly suggests that AGRP has α-MSH-
independent functions at fish MC4R, as reported in the mammalian systems (33, 50, 59). To 
test this hypothesis we developed a HEK-293 cell line stably expressing sea bass MC4R and 
a reporter gene under the control of a promoter carrying tandem repetitions of cAMP-
responsive elements. We also synthesized zebrafish AGRP (83-127) using Fmoc synthesis. It 
has been previously demonstrated that AGRP 83-132 is the active form in the mammalian 
central nervous system (24). Cell incubation with mimetic (MTII) and endogenous (α-MSH) 
melanocortin peptides stimulated galactosidase activity within the nanomolar range. Unlike 
in mammals, the α-MSH-induced activation was greater than that produced by β-MSH. The 
sea bass MC4R was stimulated with monkey β-MSH, which is only 55% identical to sea 
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bass β-MSH, so no definitive conclusion can be drawn. Diacetyl-MSH was the most potent 
melanocortin to stimulate sea bass MC4R-induced galactosidase activity, showing an EC50 
value about 8 times lower than found for α-MSH. However, the EC50 value of the cAMP 
mediated-galactosidase activity increased 160 and 200 times when cells were incubated with 
desacetyl-MSH and ACTH, respectively. This demonstrates that sea bass MC4R is activated 
with lower efficiency by human ACTH than MSHs and suggests that the acetylation level is 
critical for the activation of the sea bass receptor. Acetylation plays a crucial role in the 
biological activity of neuropeptides. In mammals, desacetyl-MSH is more abundant than α-
MSH in the brain (9) but, in contrast to our results, it activates mouse MC4R more efficiently 
than the acetylated peptide (48). However, it has also been reported that α-MSH is more 
efficient than desacetyl-MSH when activating MC4R in absence of IBMX, suggesting that 
pretreatment of cells with this phosphodiesterase inhibitor masks the signalling differences 
between both peptides (31). Accordingly, the intracerebroventricular administration of α-
MSH more potently inhibits food intake than desacetyl-MSH (31). Our experiments support 
the masking effect of the IBMX treatment since they were performed in the absence of the 
inhibitor. All three MSH isoforms have been described in fish pituitary (27) and the 
regulation of MSH acetylation seems to be an important mechanism for the background 
adaptation (3). There is no information about the regulation of isoforms acetylation in the fish 
hypothalamus but our results support a possible regulation of MSH acetylation in the same 
organ.   
None of the synthetic (HS024 and SHU9119) or endogenous (AGRP) MC4R antagonists had 
any effect on sea bass MC4R-mediated galactosidase activity but all three peptides acted as 
competitive antagonists at the sea bass receptor activity in the absence of IBMX. Both 
SHU9119 and AGRP were more efficient than HS024 when MTII-stimulated galactosidase 
activity decreased. The data show that all three antagonists are suitable for physiological 
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studies in sea bass. As expected, when IBMX was added to the incubation medium, the EC50 
value of the MTII-induced galactosidase activity decreased. Therefore, the use of IBMX 
increases the sensitivity of the assays to evaluate the activation of positively cAMP-coupled 
receptors. Under the above conditions, AGRP competitively antagonized the effects of MTII 
on sea bass MC4R activity in a similar manner to that observed without IBMX but severely 
decreased the basal activity of the sea bass MC4R, just as an inverse agonist should do. These 
results were corroborated by incubation of cells with MTII and AGRP in the presence of 
IBMX. At the lowest doses of MTII (10-10-10-9 M) the addition of 10-6 M AGRP kept the sea 
bass MC4R activity at around 30 % of the basal level. Competitive antagonism by AGRP on 
fish MC4R was reported earlier (57) but the agonistic action is newly reported here. 
However, we have demonstrated that the AGRP inverse agonism depends on treatment of the 
cells with IBMX. To the best of our knowledge, all assays reporting AGRP effects on 
melanocortin receptors involved IBMX-pretreated cells. Only one study has reported the 
effect of phosphodiesterase inhibitor on α-MSH-induced receptor activation, showing IBMX-
dependent differences in the intracellular signalling (31). These authors defended the view 
that the measurement of cAMP after pre-treatment of cells with IBMX does not truly reflect 
the melanocortin receptor signalling. Therefore, we thought initially that the inverse agonism 
of AGRP on melanocortin receptors could be an artefact of the use of IBMX in the incubation 
medium. IBMX modifies the intracellular levels of cAMP through degradation but also 
interferes with their binding to the target enzyme, cAMP-dependent protein kinase A (PKA). 
Therefore, IBMX increases the basal activity of PKA and inhibits the activation promoted by 
cAMP (62). However, we developed the same experiment using HEK cells stably 
overexpressing sea bass MC5R and no effects of AGRP by itself or reducing MTII-induced 
galactosidase activation (competitive antagonism) were observed with or without IBMX 
treatment (unpublished results, Sánchez E, Rubio VC and Cerdá-Reverter JM). These results 
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demonstrate that the AGRP agonism is specific for the MC4R and strongly depends on the 
phosphodiesterase inhibition in vitro. A possible explanation for these results would involve 
an AGRP-induced conformational change of the MC4R, leading to the activation of the 
intracellular phosphodiesterase system. This activation would reduce the cAMP intracellular 
levels imposed by the constitutive activity of the MC4R, thus decreasing the activation of the 
PKA. Overexpression in vitro of the MC4R, but not MC5R, could dramatically increase 
adenylyl cyclase activity because of its constitutive nature. Therefore, this over-activation of 
adenylyl cyclase could induce high levels of phosphodiesterase activity and this could explain 
why the effects of AGRP in vitro can only be observed after proper inhibition of 
phosphodiesterase activity. Alternatively, phosphodiesterase was shown to interact with 
arrestins to regulate the branching of signalling from G-coupled receptors (23). 
Phosphodiesterases bind arrestins and are recruited to the occupied receptors, limiting the 
cAMP accumulation in localized domains. The phosphodiesterase binding to arrestins has 
been also proposed to control the PKA-phosphorylation of the β-adrenergic receptor 
regulating the efficiency of the receptor switch from Gs- to Gi-proteins. This exchange could 
decrease the rate of cAMP generation because Gi activation inhibits adenylyl cyclase and 
couples the receptor to Gi-linked pathways (5). Interestingly, it has been reported that AGRP 
induces arrestin-mediated endocytosis of the human MC4R (8) which exhibits a constitutive 
traffic in hypothalamic neurons (46). Intracellular signalling pathways through which 
melanocortin receptors exert their effects are not well understood. Activated melanocortin 
receptor binds to Gs and this leads to stimulation of adenylyl cyclase while increased 
concentrations of intracellular cAMP activate PKA. Active PKA initiates the transcription of 
new genes by phosphorylation and activation of cAMP-responsive element binding protein 
(CREB). However, other intracellular signalling pathways, including mitogenic activated 
protein (MAP) kinase (53) and inositol/Ca2+ (49) and probably adenosine monophosphate 
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activated-protein kinase (AMPK) pathways (45) have also been reported to be involved in 
MC4R intracellular signalling. A very recent paper has demonstrated that the disruption of 
regulatory subunit RIIβ of PKA in agouti lethal yellow mice partially reverses obesity, 
possibly by increasing kinase activity (25). This suggests that the agouti-induced metabolic 
syndrome is mediated by down-regulation of the PKA, probably mediated by reduction of 
cAMP levels.  
Our results demonstrate that the competitive antagonism of AGRP is not dependent on the 
presence of IBMX, suggesting that both AGRP agonism and antagonism in the sea bass 
MC4R system are mediated through different intracellular signalling pathways with 
differential sensitivities to phosphodiesterase inhibitors. More experiments on intracellular 
signalling pathways of the MC4R must be made to corroborate this hypothesis, which opens 
up new targets for the treatment of melanocortin-induced metabolic syndrome.  
The AGRP-mediated decrease of basal galactosidase activity in HEK cells expressing sea 
bass MC4R suggests that the receptor may be constitutively activated. The constitutive 
activity of the mammalian MC4R has already been demonstrated in vitro and in vivo (see 
introduction for references). It has been proposed that the N-terminal domain functions as a 
tethered intramolecular ligand preserving the constitutive activity of the receptor. This 
constitutive activity of the MC4R is supposed to impose an inhibitory tone on food intake 
that is regulated by AGRP binding (22). Therefore mutations like R18C within the N-
terminal domain that do not impair the binding of agonist but can drastically reduce the 
constitutive activity which leads to obesity in humans. Interestingly, sea bass MC4R exhibits 
an arginine (R) residue N-terminally flanked by an asparagine residue (N) in a similar 
position to that observed in humans. We do not know if the putative constitutive activity of 
the sea bass MC4R can operate in vivo but the physiological data reported here support the 
idea. Progressive fasting does not increase hypothalamic POMC expression in the sea bass as 
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previously observed in the goldfish (15) and zebrafish (58), suggesting a limited production 
of agonist during negative energy balance states. In the latter species, fasting dramatically 
induces hypothalamic AGRP expression (58), suggesting a downregulation of MC4R 
signalling in the absence of a decrease of agonist production, through AGRP binding. In this 
paper, we further explore two additional levels that can potentially regulate the melanocortin 
signalling in the absence of variations of hypothalamic POMC expression. These levels 
included the down-regulation of the hypothalamic receptor expression and the peripheral 
production of melanocortins. Similar to that reported in barfin flounder (Verasper moseri, 
39), the hypothalamic expression of MC4R does not change during progressive fasting. It has 
been demonstrated that peripherally administrated melanocortins can mediate variations of 
the central melanocortin activity via MC4R (34). However fasting did not induce any change 
in the pituitary POMC expression or α-MSH plasma levels in the sea bass, suggesting that 
peripheral melanocortins are not responsible for the downregulation of melanocortin 
signalling via brain receptors during progressive fasting. Differential regulation of POMC 
processing or N-acetylation of MSH during fasting, potential regulatory levels of the 
melanocortin signalling in the absence of POMC production, remain unexplored and are 
under study in our laboratory. 
 
PERSPECTIVES AND SIGNIFICANCE 
Central melanocortin signaling plays a key role in the regulation of energy balance in 
mammals by exerting an inhibitory tone on food intake and by stimulating energy 
expenditure. Most actions on energy balance are mediated via central MC3R and MC4R. The 
later receptor displays a constitutive activity regulated by AGRP binding which may work as 
competitive antagonist or inverse agonist. Our results demonstrate that fish MC4R also 
exhibits constitutive activity and that MSH/AGRP/MC4R interaction works in a similar way 
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to that reported in mammalian systems. It supports the evolutionary conservation of the 
AGRP/MC4R interactions as well as the role of the melanocortin system in the control of 
energy balance. The absence of regulation in central and peripheral POMC and MC4R 
expression during progressive fasting supports a physiological role for inverse agonism in 
fish. In addition, our results show that the inverse agonism, but not the competitive 
antagonism, depends on inhibition of the intracellular phosphodiesterase system, which 
suggests that both systems operate through different intracellular pathways in the regulation 
of CREB protein activation. The functional homology between mammalian and fish 
melanocortin system permits speculate that the mammalian AGRP/MC4R interaction is also 
dependent on the intracellular phosphodiesterase system. This view opens up new targets for 
the treatment of obesity in humans. Our future research will focus the study of activity of the 
different intracellular pathways after AGRP stimulation of the HEK cells stably expressing sb 
MC4R in presence or absence of phosphodiesterase inhibitors.  
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Figure 1. Nucleotide and deduced amino acid sequence of sea bass melanocortin receptor 4 
(MC4R). Nucleotide and amino acid sequence numbers are indicated on the left and right 
sides, respectively. Grey boxed amino acids indicate putative transmembrane domains 
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predicted using Split 4.0 Server (http://split.pmfst.hr/split/4/). Open boxes frame tripeptide 
sequences that conform with the consensus sequence for N-linked glycosylation sites. Oval 
frames enclose possible phosporylation sites. Sequences of primers used in RT-PCR 
amplification are underlined. Sea bass MC4R sequence accession number FM253127.  
 
Figure 2. Alignment of melanocortin receptor amino acid sequences from human. Sea bass 
MC4R sequence is highlighted in bold letters. Dots indicate amino acids identical to the top 
sequence. Dashes were introduced to improve alignment. Grey boxes show putative 
transmembrane domains predicted with Split 4.0 Server (see Fig. 1). Arrows indicate fully 
conserved cysteine residues in all melanocortin receptors.   
 
Figure 3. Distribution of sea bass MCR4 mRNA expression in different tissues as revealed 
by RT-PCR assay followed by Southern blot hybridization. (A) Phosphoimaging screen 
showing a Southern blot analysis of the sea bass receptor following RT-PCR assays. (B) 
Ethidium bromide-stained agarose gels showing RT-PCR amplifications of sea bass 18S 
RNA.   
 
Figure 4. Schematic drawings of the successive rostrocaudal transverse sections of the sea 
bass brain showing the distribution of MC4R-expressing perikarya (black dots) as revealed 
by in situ hybridization. Number of dots roughly represents expression density but 
quantitative studies were not done. Scale bar = 1 mm. Abbreviations: (AC) anterior 
commissure, (AP) accessory pretectal nucleus, (CCe) corpus of the cerebellum, (CP) central 
posterior thalamic nucleus, (Dc2) subdivision 2 of the central part of the dorsal 
telencephalon, (Dld) laterodorsal part of the dorsal telencephalon, (Dlv2) subdivision 2 of the 
lateroventral part of the dorsal telencephalon, (Dm2, Dm3 and Dm4) subdivision 2, 3 and 4 
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of the medial part of the dorsal telencephalon, (Dp) posterior part of the dorsal telencephalon, 
(DP) dorsal posterior thalamic nucleus, (DT) dorsal tegmental nucleus nucleus, (HaCo) 
habenular commissure, (LC) locus coeruleus, (LT) lateral thalamic nucleus, (nIV) trochlear 
nerve nucleus, (NAPv) anterior periventricular nucleus, (NAT) anterior tuberal nucleus, (NC) 
cortical nucleus, (NCLI) central nucleus of the inferior lobe, (NDLIl) lateral part of diffuse 
nucleus of the inferior lobe, (NDLIm) medial part of diffuse nucleus of the inferior lobe, 
(nFR) nucleus of the fasciculus retroflexus, (NGa and NGp) anterior and posterior parts of 
the glomerular nucleus, (NGT) tertiary gustatory nucleus, (NHd) dorsal part of the habenular 
nucleus, (NHv) ventral part of the habenular nucleus, (NLTd) dorsal part of the lateral tuberal 
nucleus, (NLTi) inferior part of the lateral tuberal nucleus, (NLTl) lateral part of the lateral 
tuberal nucleus, (NLTm) medial part of the lateral tuberal nucleus, (NLTv) ventral part of the 
lateral tuberal nucleus, (NLV) lateral valvula nucleus, (nMLF) nucleus of the medial 
longitudinal fasciculus, (NPC) central pretectal nucleus, (NPGc) commissural part of the 
preglomerular nucleus, (NPGl) lateral part of the preglomerular nucleus, (NPGm) medial part 
of the preglomerular nucleus, (NPOav) anteroventral part of the parvocellular preoptic 
nucleus, (NPOpc) parvocellular part of the parvocellular preoptic nucleus, (NPPv) posterior 
periventricular nucleus, (NPT) posterior tuberal nucleus, (nPVO) nucleus of the 
paraventricular organ, (NRLd) dorsal part of the lateral recess nucleus, (NRLl) lateral part of 
the lateral recess nucleus, (NRLv) ventral part of the lateral recess nucleus, (NRP) posterior 
recess nucleus, (NSC) suprachiasmatic nucleus, (NSV) nucleus of the vascular saccus, (OT) 
optic tectum, (P) pituitary, (PC) paracommissural nucleus, (pgd) dorsal periglomerular 
nucleus, (PGZ) periventricular gray zone of the optic tectum, (PM) magnocellular preoptic 
nucleus, (PPd) dorsal periventricular pretectal nucleus, (PPv) ventral periventricular pretectal 
nucleus, (PVO) paraventricular organ, (PSm) magnocellular superficial pretectal nucleus, 
(PSp) parvocellular superficial pretectal nucleus, (RS) superior reticular nucleus, (SV) saccus 
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vasculosus, (TLa) nucleus of the lateral torus, (TLo) nucleus of the longitudinal torus, (TPp) 
periventricular nucleus of the posterior tuberculum, (TS) semicircular torus, (VCe) valvula 
cerebelli, (Vd) dorsal part of the ventral telencephalon, (Vi) inferior part of the ventral 
telencephalon, (Vl) lateral part of the ventral telencephalon, (VL) ventrolateral thalamic 
nucleus, (VM) ventromedial thalamic nucleus, (Vp) postcommissural part of the ventral 
telencephalon, (Vs) supracommissural part of the ventral telencephalon, (Vv) ventral part of 
the ventral telencephalon.  
 
Figure 5. Brightfield (A, C, E, G, I, K) and darkfield (B, D, F, H, J, L) micrographs of 
transverse sections of the sea bass brain from rostral preoptic area (A) to rombemcephalon 
(K). (A, B) Positive MCR4 neurons placed within the rostral divisions of the preoptic area, 
parvocellular (NPOpc) and anteroventral parts of the parvocellular preoptic nucleus (NPOav). 
(C, D) MC4R-expressing neurons at the magnocellular preoptic nucleus (PM) and anterior 
periventricular nucleus (NAPv). (E, F) MC4R neurons at the tuberal hypothalamus; dorsal 
part of the lateral tuberal nucleus (NLTd), ventral part of the lateral tuberal nucleus (NLTv) 
and ventral part of the lateral recess nucleus (NRLv). (G,H) MC4R expression at the 
hypothalamic inferior lobe; medial part of the diffuse nucleus of the inferior lobe (NDLIm), 
dorsal part of the lateral recess nucleus (NRLd) and NRLv ventral part of the lateral recess 
nucleus. (I, J) micrography showing MC4R expression within ventromedial thalamus (VM). 
(K, L) MC4R expression within superior part of the reticular formation (RS) and possibly 
including neurons from the locus coeruleus. Scale bar = 200 μm.  
Figure 6. Effects of progressive fasting on pituitary and hypothalamic POMC, pituitary 
MC4R expression (A) and plasma α-MSH levels (B). Gene expression levels were expressed 
as ratio specific mRNA/18S RNA. Data are mean ± SEM (n=8).  
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Figure 7. A) Saturation curve were obtained with [125I][Nle4, D-Phe7]α-MSH and the 
figure shows specific binding (!) and binding in the presence of 10 µM cold [Nle4, D-
Phe7]α-MSH (Δ). Lines represent the computer-modelled best fit of the data assuming that 
ligands bound to one-site. B) Pharmacological properties of melanocortin agonist and 
antagonist at human embryonic kidney 293 cells (HEK-293) stably expressing both sea bass 
MC4R and a cAMP-responsive β-galactosidase reporter gene in absence of 
phosphodiesterase inhibitors (IBMX). Data were normalized to protein levels and expressed 
as percentage of the basal levels. Experiments were performed using quadruplicate data 
points and repeated at least three independently.  
 
Figure 8. Effects of synthetic (Shu9119 and HS024) and endogenous antagonist (AGRP) on 
MTII-stimulated galactosidase activity in HEK-293 cells stably expressing both sea bass 
MC4R and a cAMP-responsive β-galactosidase reporter gene in absence of 
phosphodiesterase inhibitors (IBMX). Data were normalized to protein levels and expressed 
as percentage of the basal levels. Experiments were performed using quadruplicate data 
points and repeated at least three independent times. 
 
Figure 9. Effects of phosphodiesterase inhibitors (IBMX) on pharmacological properties of 
agonist (MTII) and antagonist (AGRP) at human embryonic kidney 293 cells (HEK-293) 
stably expressing both sea bass MC4R and a cAMP-responsive β-galactosidase reporter gene. 
Data were normalized to protein levels and expressed as percentage of the basal levels. 
IBMX alone induced an increase in the β-galactosidase activity of 131% ± 8.57 when 
compared to the basal enzyme activity in absence of the phosphodiesterase inhibitor. 
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Experiments were performed using quadruplicate data points and repeated at least three 
independent times.  
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D. rerio MC2R      ------------------------------------------------MNPS.ESPSS---------IHTDCAEVQ.PGQ..LVIA.A..S..L.....VI..........C...N...FNTIS. : 68 
H. sapiens MC4R    VSNGSETIIITLLNS-TDTDAQSFTVNIDNVIDSVICSSLLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLM :218 
R. norvegicus MC4R ........V......-......................................................R.................V.......................V............ :218 
G. gallus MC4R     ........V.....N-.........I................................................V..T....................V......S......I..........M. :217 
D. labrax MC4R     ...A....V.A.I.GGKL.IPVQLIKSM...F..M.............A......I......R....V.LR.AMLV..S..TC.I..........E.TT.L...........V...........L :219 
T. rubripes MC4R   ...A....V.A.I..G.L.IPATLIKSM...F..M.............A......I......R....V.LR.ASLV..S..TC.....V...V..E.TT.L...........V...........L :214 
D. rerio MC4R      ...A...VVMA.ITGGNL.NRE.IIK.M...F..M.........W...A......I......R......QR.A.T..T...TF.....V...V..E.TT.L....S..................L :216 
H. sapiens MC1R    G..VL..AV.L..EAGALVARAAVLQQL.....VIT...M.S.L.F.GA......IS.....R..S.V.LP.ARQAVAA..V.SV.FST...A.Y.HV..LL..VVF.LA..V...V.....LAR :213 
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D. rerio MC1R      ...VV..LFML.TEHGLLLVTAKMLQHL.....IM....VVS.LSF.CT..A...I......R..S...TQ.AVG..LVV.L.SIT.SS...V.HTDN...A..V.F.GVT.VFT.V..L...IL :218 
H. sapiens MC3R    ...AL...M.AIVH.DYL.FEDQ.IQHM..IF..M..I..V....N..A......V......R..S....RKALTL.VA..VC.G.C.VV..V..E.KM..V.......A.ML..GT.......F :250 
D. rerio MC3R      ...SL...V.AV...RLLVASDQLCRLMH..C..M..I..V....N..A......V......R..S.V..R.ALVA.AV..LV.V.C..V..V..E.KT..V.......A..V...T.......L :213 
H. sapiens MC5R    M.SAW...T.Y...NKHLVI.DA.VRH....F..M..I.VV..M....A......V......R..H...AR.S.A..AG...F..GC..V..L..E.TY..L...S...A..F.LV...I....L :211 
T. rubripes MC5R   ...A......Y...NKQLIAEDHLIRQL...F..M..I.VV..M....A......V......R.......R.A.C..GG..TF..GC..V......TTP.....VC...A..LI.....S...ML :222 
D. rerio MC5Ra     ...AW...V.Y..TNRQLVVEDH.IRQM...F..M..I.VV..M....A......V......R.......R.AAL..GG..TF..GC..V......NTS..V..VS...I.........S...ML :204 
D. rerio MC5Rb     ...AW...V.H..ANRSLVIEDH.IRQM...F..L..I.VVG.MW...A......V......R.......R.A..L.GS..TFS.SC..I......TKP.VV..VA...A..LM.....S....L :213 
H. sapiens MC2R    LYKIL.N.L.I.R.MGYLKPRG..ETTA.DI...LFVL...G..F..SV..A...I...H..R..S.V.MR.TVVVLTV..TF..GT..TMV.F.HHVPTV.TFTSL.PL..VFILC.......L :199 
T. rubripes MC2R   .TKTW.NLM..FAEVGHLRKVGFSERKA.D.V..LL.M.F.G..F.F.A......I...H..R......MQ.T.A.LGL..TT.G..AM.MVRFF..NLIMS.FVVF.IIS..IIYI...Y..IL :189 
D. rerio MC2R      F.KAL.N.LLLFKDAGRLNLRGP.ELK..DIM..LL.MCF.S..F.I.A......IS..H..R..ML..MR..L..LFT..VL.GT..A.MVGFFEAAT.T.FF.VL...A.L.ILL.......L :193 
H. sapiens MC4R    ARLHIKRIAVLPGTGA------IRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQNPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY---- :332 
R. norvegicus MC4R ...............T------...............................L............................AV......................F.....I.E.PG..---- :332 
G. gallus MC4R     ..M...K........P------......................................Y............F.................F...............CN.R.....PGK.---- :331 
D. labrax MC4R     ....M....A...NAP------.H.R............................LM.T..R....T....Q..M.........V...I...F....M.......F..S--HA.LCV-------- :327 
T. rubripes MC4R   ....M....AM..NAP------.H.R..L.........L...............LM.T..K....T.......M.........V...I...F....M.......F..S--QM.VCM-------- :322 
D. rerio MC4R      ....M....A...N.P------.W.A........I...L...............LM....R............M.........V.......F....M.......C..W--Y..AS.CV------ :326 
H. sapiens MC1R    .CQ.AQG..R.HKRQRP-----VH..FGL...V.....L.I.FL..G......TLIVL..EH.T.G.IFKN...F.A..I..A........FH.....R.L..VLT.SW--------------- :317 
T. rubripes MC1R   .HV.SR..MAFHKNRR--------.STS..........L...IL..G.......LILT..TSVF.N.YFRN...F....I...L.......Y........LQ.LVL.SWCF.P----------- :300 
D. rerio MC1R      .HV.SR..TA.HKSRR--------.TTS..........L...IL..G.......LILT..T....K.YF.....F....I...L.......Y........L..L.F.SWCFAV----------- :323 
H. sapiens MC3R    ....V....A..PADG----VAPQ.HSC....V.I...L...IF.........VLI.T..T....I.YTA...T..V......V.......F..L...N..R..L.GCNGMN.G---------- :360 
D. rerio MC3R      ....VQ...A..PAAPGAGNPAP..RSC....V.IS..L....C..........LLV...HH.L.L.Y....TT..V......V.......C..L.M.......L.-CFGCQPAL--------- :327 
H. sapiens MC5R    ..T.V....A...ASS------A..RTS.Q..V.V.M.L...T..........TLML.....L..SR......M.........VM......F....M..........RGFRIA.SFPR.D---- :325 
T. rubripes MC5R   ..S.V....A...SNS------.H.R.S..........L.I.II..........LM....R.L..M.......M.........V.......F....M........F..S.RNT.STICTLPGKY :340 
D. rerio MC5Ra     ..S.V....A...YNS------.H.R.S..A.V.....L.I.I...........LM....R.L..M.......M.........V.......F....M...L.......S.RNVFGM.R------ :316 
D. rerio MC5Rb     ..S.V..M.A...YN.N-----...R.S....V.....L.I.I...........LM....R.I..........M.........V............M.......V..EG.RSF.NMV.K.---- :328 
H. sapiens MC2R    ..S.TRK.ST..RAN-------------..........L...IF.....V..VLLMTF..S....A.Y..L.QVNGM.....AV...F...F..P...DA..KM.F.SRYW------------- :297 
T. rubripes MC2R   ..V.ARK..A..NGSGKH-QHQR.W.HG.R.IL.....F.A.M............LMA..M....E.YR.M.Q.H.V.L.SHAL...V...F.IP...H..RRMLP.LNWRWR----------- :301 
D. rerio MC2R      ..H.AN...SM..AQ.QH-RKS-----GLR..L....KK....A.....S...LIMMI..E.Q..E.YR.L.Q.HVV.LVSHAV...A.N.F..V...N.Y.KQLLSSASRICKRCA------- :304
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TABLE 1 
EC50-IC50 and Kd Values from Respective Gene Reporter Activation and Saturation Curves for Melanocortin Analogs on Seabass 
MC4R Expressed in HEK-293 Cells. 
 
 
 
 
[125I]-NDP-
MSH  
(nM) 
 
Desacety
l-MSH 
(nM) 
 
α-MSH 
(nM) 
 
Diacetyl-
MSH 
(nM) 
 
MTII 
(nM) 
 
Monkey 
β-MSH 
(nM) 
 
Human
ACTH 
(nM) 
 
AGRP 
(nM) 
MTII  
+ 
HS024(1μM) 
(nM) 
MTII 
+ 
SHU9119(1μM)
(nM) 
MTII 
+ 
AGRP (1μM) 
(nM) 
Kd 0.336           
EC50  15.13 0.822 0.094 0.31 3.33 18.8  17 120 85 
IC50        1.14    
